I

Immunic

D
IMUX
USD
-0.02
(-1.6667%)
Market Closed
41,138.00
Volume
-0.92
EPS
-
Div Yield
-0.786667
P/E
106,293,238.88
Market Cap
Today
-1.6667%
1 Week
-1.667%
1 Month
-23.377%
6 Months
-15.714%
12 Months
2.609%
Year To Date
-21.070%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
I
IMGN
(%)
USD
I
IONS
-0.62
(-1.5869%)
USD
I
IMVT
-1.47
(-4.6785%)
USD
I
INSM
-1.14
(-1.5653%)
USD
I
IMAX
-0.01
(-0.0405%)
USD
I
IMAB
-0.01
(-0.9174%)
USD

Title:
Immunic

Sector:
Healthcare
Industry:
Biotechnology
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Do you need help or have a question?
Contact Us